30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
The best predictor of CDR at 36 months was M, a DCB reflecting recall ability (area under the curve = 0.84), outperforming traditional scores. 5 key findings →
Participants: 330 Evidence: low
Full summary, score breakdown and related studies → Original source
Average compliance by time of day ranged from 90.2% for morning sessions, to 77.9% for afternoon sessions, and 84.4% for evening sessions. 5 key findings →
Participants: 120 Evidence: low
Full summary, score breakdown and related studies → Original source
Higher concentrations of pTau181 and GFAP were associated with slower responses on working memory tasks (pTau181: β = 0.261; p = 0.007; GFAP: β = 0.175, p = 0.036), and higher β-amyloid 42/40 ratio was associated with better vocabulary (β = 0.260, p = 0.009). 4 key findings →
Participants: 114 Evidence: low
Full summary, score breakdown and related studies → Original source
Age- and sex-specific reference values were generated for three DANA tasks. 5 key findings →
Participants: 932 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our results demonstrated that dual-task could significantly improve the ability to predict cognitive impairment based on gait parameters such as gait speed (GS) and stride length (SL). 5 key findings →
Participants: 38 Evidence: low
Full summary, score breakdown and related studies → Original source
The search for early biomarkers of mild cognitive impairment (MCI) has been central to the Alzheimer's Disease (AD) and dementia research community in recent years. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The Alzheimer's Disease Neuroimaging Initiative (ADNI) Administrative Core oversees and coordinates all ADNI activities, to ensure the success and maximize the impact of ADNI in advancing Alzheimer's disease (AD) research and clinical trials. 1 key finding →
Participants: 500 Evidence: low
Full summary, score breakdown and related studies → Original source
Digital cognitive testing using online platforms has emerged as a potentially transformative tool in clinical neuroscience. 3 key findings →
Participants: 325 Evidence: low
Full summary, score breakdown and related studies → Original source
BackgroundEarly diagnosis of early-onset dementia (EOD) is often challenging. 1 key finding →
Participants: 54 Evidence: low
Full summary, score breakdown and related studies → Original source
Although a small-scale study (n = 60), it suggests that older adults operate in larger geographic spaces than in the areas where they reside. 5 key findings →
Design: cross-sectional Participants: 60 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our findings suggest that VStore is a promising assessment that engages standard cognitive domains and is sensitive to age-related cognitive decline. 2 key findings →
Participants: 142 Evidence: low
Full summary, score breakdown and related studies → Original source
The population with dementia is expected to rise to 152 million in 2050 due to the aging population worldwide. 2 key findings →
Participants: 64 Evidence: low
Full summary, score breakdown and related studies → Original source
MTD demonstrated high usability as defined by completion rates in this research sample that includes a broad age range, though participation rates are lower in individuals with cognitive impairment. 5 key findings →
Participants: 1,769 Evidence: low
Full summary, score breakdown and related studies → Original source
The overall sample had a mean ACE-III score of 91/100 (SD 6) with 15.7% (16/102) scoring at or below the cut-off score considered to represent objective cognitive impairment. 2 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
The German BHA and BHS are more sensitive to mild NCD and non-AD presentations than the MoCA and thus have a high potential to identify patients with NCD in primary care earlier than currently used screens. 1 key finding →
Participants: 67 Evidence: low
Full summary, score breakdown and related studies → Original source
Our results suggest that BC-Assess could serve as an effective alternative tool to DSRS for grading dementia severity, particularly in cases where DSRS, or other global assessments, may be challenging to obtain due to logistical and time constraints. 5 key findings →
Participants: 1,751 Evidence: low
Full summary, score breakdown and related studies → Original source
Among these patients, 29 were diagnosed with CHE by the PHES test (35.36% prevalence) and 28 of those obtained equal diagnosis by the Stroop EncephalApp (96.6% sensitivity). 5 key findings →
Design: cross-sectional Participants: 82 Evidence: low
Full summary, score breakdown and related studies → Original source
In this pragmatic prospective cohort study we found that the PDT was used by elderly care physicians, with mediocre user satisfaction. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
This pilot study indicates that Silvia-Rx's digital cognitive program is feasible for people diagnosed with MCI, suggests potential for improving cognitive function, though further research with large sample size is needed to confirm these results. 5 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is common in Parkinson's disease (PD) but measures that track cognitive change in PD are lacking. 4 key findings →
Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Rapid eye movement sleep behavior disorder (RBD) is common in Parkinson disease (PD), but its relationship to the varied neurotransmitter deficits of PD and prognostic significance remain incompletely understood. 4 key findings →
Participants: 35 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The protein beta-amyloid is said to be central to the disease process of Alzheimer's disease (AD). 4 key findings →
Design: cross-sectional Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We developed and validated the Mini-Addenbrooke's Cognitive Examination (M-ACE) in dementia patients. 4 key findings →
Participants: 25 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recently, there has been growing interest in the glymphatic system (the functional waste clearance pathway for the central nervous system and its role in flushing solutes (such as amyloid ß and tau), metabolic, and other cellular waste products in the brain. 4 key findings →
Participants: 36 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cognitive impairment is a frequent feature of COPD. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events